- Home
- ABBV
ABBV
AbbVie Inc.
as 11-20-2024 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 348.0B | IPO Year: | N/A |
| Target Price: | $206.00 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.87 | EPS Growth: | -21.44 |
| 52 Week Low/High: | $137.65 - $207.32 | Next Earning Date: | 10-30-2024 |
| Revenue: | $55,533,000,000 | Revenue Growth: | 0.72% |
| Revenue Growth (this year): | 5.27% | Revenue Growth (next year): | 5.65% |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Zacks
20 hours ago
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Zacks
2 days ago
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
Motley Fool
2 days ago
Where Will AbbVie Be in 5 Years?
Zacks Small Cap Research
2 days ago
RVPH: Year-End OLE Update
Pharma Voice
2 days ago
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
MT Newswires
3 days ago
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating
Zacks
3 days ago
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
PR Newswire
3 days ago
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.